Paragon Associates & Paragon Associates II Joint Venture’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio ENTL Stock Details ENTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-35,000	Closed	-$580K	–	25
2017 Q2	$580K	Buy	35,000 +25,000	+250%	+$348K	0.66%	13
2017 Q1	$138K	Buy	+10,000	New	+$161K	0.15%	20

Other funds holding ENTL

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

DGI

Discovery Group I Chicago, Illinois $262M AUM 29.24% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's ENTL Position: Q3 2017 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q3 2017, closing a stake of 35,000 shares — an estimated $580K sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in ENTL in Q1 2017 and held it in 2 quarters. The position peaked at $580K in Q2 2017. 72 funds tracked by Wall St. Rank hold ENTL as of Q3 2017.

Paragon Associates & Paragon Associates II Joint Venture reported no remaining Entellus Medical, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Paragon Associates & Paragon Associates II Joint Venture sold 35,000 Entellus Medical, Inc. Common Stock shares in Q3 2017, an estimated $580K.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in Entellus Medical, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
Paragon Associates & Paragon Associates II Joint Venture's Entellus Medical, Inc. Common Stock position peaked at $580K in Q2 2017.
72 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q3 2017.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q3 2017, filed 13 Nov 2017.